Sanofi’s $11.6bn Bioverativ Purchase Looks Hit-And Miss After Phase 3 Rare Diseases Drug Runs Into Trouble

Why It Matters

The Phase 3 failure threatens Sanofi’s ability to recoup its $11.6 bn Bioverativ outlay and underscores the risk inherent in rare‑disease drug development, influencing investor confidence and future R&D budgeting.

Key Takeaways

• Sanofi paid $11.6 bn for Bioverativ in 2018
• Riliprubart failed Phase 3 MOBILIZE trial in CIDP patients
• Altuviiio posted $354 m Q1 2026 sales, a rare‑disease blockbuster
• Enjaymo sold to Recordati for $825 m after CAD approval
• Pipeline doubts persist until additional Bioverativ assets prove profitable

Pulse Analysis

Sanofi’s acquisition of Bioverativ was one of the most high‑profile rare‑disease deals in recent history, costing roughly $11.6 bn. The French group hoped the purchase would provide a pipeline of niche therapeutics and a steady revenue stream, a bet that initially seemed justified when Altuviiio, a factor‑VIII fusion protein for haemophilia A, launched and quickly generated $354 m in first‑quarter sales. The deal also brought in a suite of complement‑targeting candidates, most notably riliprubart, a selective C1s inhibitor designed to curb the inflammatory cascade in chronic inflammatory demyelinating polyneuropathy (CIDP). However, the recent termination of the MOBILIZE Phase 3 trial after an interim analysis showed no efficacy has shaken confidence in the pipeline’s depth.

The failure of riliprubart highlights the scientific and commercial challenges of translating complement inhibition into meaningful outcomes for rare neurological disorders. While the drug demonstrated a clean safety profile, the lack of efficacy in a refractory CIDP population suggests that the disease’s pathophysiology may be more complex than anticipated, or that patient selection criteria need refinement. This setback forces Sanofi to reassess its R&D allocation, potentially diverting resources toward more promising assets such as Altuviiio or exploring partnerships to share development risk.

For investors and industry observers, the Bioverativ story serves as a cautionary tale about the volatility of rare‑disease investments. The blockbuster status of Altuviiio provides a partial offset, yet the $825 m divestiture of Enjaymo and the lingering doubts over other pipeline candidates mean the acquisition’s overall return remains uncertain. Sanofi’s next moves—whether accelerating other Bioverativ programs, seeking external collaborations, or trimming the portfolio—will be critical in determining whether the $11.6 bn price tag ultimately proves a strategic win or a costly misstep.